Meanwhile, TZDs and other PPARγ ligands led to the suppression of multiple “bad” adipokines, such as resistin, α1-acid glycoprotein, and haptoglobin, which probably contributed to the anti-obesity effect of these drugs [55,56,57]. Here, PPARG is linked to obesity disorder.